


This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1. (Currently Amended): A compound according to Compounds of the formula I



I


in which

D is absent or

is a saturated, fully or partially unsaturated 3- to 4-membered alkylene chain, in which from 1 to 3 carbon atoms may be replaced by N and/or 1 or 2 carbon atoms may be replaced by 1 or 2 O and/or 1 or 2 S atoms, but where at most up to 3 carbon atoms are replaced and where, in addition, the alkylene chain and/or a nitrogen present therein may be monosubstituted, disubstituted or trisubstituted by Hal, A, $-\text{[C}(\text{R}^3)_2\text{]}_n\text{-Ar}$, $-\text{[C}(\text{R}^3)_2\text{]}_n\text{-Het}$, $-\text{[C}(\text{R}^3)_2\text{]}_n\text{-cycloalkyl}$, OR^2 , $\text{N}(\text{R}^2)_2$, NO_2 , CN , COOR^2 , $\text{CON}(\text{R}^2)_2$, NR^2COA , $\text{NR}^2\text{SO}_2\text{A}$, COR^2 , SO_2NR^2 and/or $\text{S}(\text{O})_m\text{A}$, and where, furthermore, one CH_2 group in the alkylene chain may also be replaced by a $\text{C}=\text{O}$ group,

M is a phenyl ring or an aromatic heterocyclic ring, which may contain 1-2 N, O and/or S atoms,

R^1 and R^1' are each, independently of one another, H, Hal, A, OR^2 , $\text{N}(\text{R}^2)_2$, NO_2 , CN , COOR^2 , $\text{CON}(\text{R}^2)_2$, $\text{C}(\text{=S})\text{N}(\text{R}^2)_2$, $-\text{[C}(\text{R}^3)_2\text{]}_n\text{-Ar}$, $-\text{[C}(\text{R}^3)_2\text{]}_n\text{-Het}$, $-\text{[C}(\text{R}^3)_2\text{]}_n\text{-cycloalkyl}$, $-\text{[C}(\text{R}^3)_2\text{]}_n\text{-N}(\text{R}^3)_2$, CN , $-\text{C}(\text{=NH})\text{-NH}_2$ which is unsubstituted or monosubstituted by $\text{C}(\text{=O})\text{R}^3$, COOR^3 , OR^3 , OCOR^3 , OCOOR^3 or by a conventional amino-protecting group, or



R^2 is H, A, $-[C(R^3)_2]_n-Ar$, $-[C(R^3)_2]_n-Het$, $-[C(R^3)_2]_n-cycloalkyl$, $-[C(R^3)_2]_n-N(R^3)_2$ or $-[C(R^3)_2]_n-OR^3$,

$R^{2'}$ is H, A, $-[C(R^3)_2]_n-Ar'$, $-[C(R^3)_2]_n-Het'$, $-[C(R^3)_2]_n-cycloalkyl$, $-[C(R^3)_2]_n-N(R^3)_2$ or $-[C(R^3)_2]_n-OR^3$,

$R^{2''}$ is H, A, $-[C(R^3)_2]_n-Ar'$, $-[C(R^3)_2]_n-cycloalkyl$, $-[C(R^3)_2]_n-N(R^3)_2$ or $-[C(R^3)_2]_n-OR^3$,

R^3 is H or A,

W is a monocyclic or bicyclic saturated, unsaturated or aromatic carbocyclic or heterocyclic ring having from 1 to 4 N, O and/or S atoms, which may be monosubstituted or disubstituted by R^2 ,

X is $CONR^2$, $CONR^2C(R^3)_2$, $-C(R^3)_2NR^2$, $-C(R^3)_2NR^2C(R^3)_2$, $-C(R^3)_2O-$, $-C(R^3)_2OC(R^3)_2-$ or NR^2CO ,

Y is alkylene, cycloalkylene, Het-diyl or Ar-diyl,

T is a monocyclic or bicyclic, saturated, unsaturated or aromatic carbocyclic or heterocyclic ring having from 1 to 4 N, O and/or S atoms which is monosubstituted or disubstituted by $=S$, $=NR^2$, $=N-CN$, $=N-NO_2$, $=NOR^2$, $=NCOR^2$, $=NCOOR^2$ or $=NOCOR^2$ and may furthermore be monosubstituted, disubstituted or trisubstituted by Hal, A, $-[C(R^3)_2]_n-Ar$, $-[C(R^3)_2]_n-Het$, $-[C(R^3)_2]_n-cycloalkyl$, OR^3 , $N(R^3)_2$, NO_2 , CN , $COOR^2$, $CON(R^2)_2$, NR^2COA , $NR^2CON(R^2)_2$, NR^2SO_2A , COR^2 , SO_2NR^2 and/or $S(O)_m A$,

A is unbranched or branched alkyl having 1-10 carbon atoms, in which one or two CH_2 groups may be replaced by O or S atoms and/or by $-CH=CH-$ groups, and/or in addition 1-7 H atoms may be replaced by F,

Ar is phenyl, naphthyl or biphenyl, each of which is unsubstituted or monosubstituted, disubstituted or trisubstituted by Hal, A, OR^3 ,

$N(R^3)_2$, NO_2 , CN , $COOR^3$, $CON(R^3)_2$, NR^3COA , $NR^3CON(R^3)_2$,
 NR^3SO_2A , COR^3 , $SO_2N(R^3)_2$, $S(O)_m A$, $-[C(R^3)_2]_n-COOR^2$ or
 $-O-[C(R^3)_2]_o-COOR^2$,

Ar' is phenyl or benzyl, each of which is unsubstituted or monosubstituted or disubstituted by Hal,

Het is a monocyclic or bicyclic, saturated, unsaturated or aromatic heterocyclic ring having from 1 to 4 N, O and/or S atoms, which may be unsubstituted or monosubstituted, disubstituted or trisubstituted by carbonyl oxygen, $=S$, $=N(R^3)_2$, Hal, A, $-[C(R^3)_2]_n-Ar$, $-[C(R^3)_2]_n-Het^1$, $-[C(R^3)_2]_n-cycloalkyl$, $-[C(R^3)_2]_n-OR^2$, $-[C(R^3)_2]_n-N(R^2)_2$, NO_2 , CN , $-[C(R^3)_2]_n-COOR^2$, $-[C(R^3)_2]_n-CON(R^2)_2$, $-[C(R^3)_2]_n-NR^2COA$, $NR^2CON(R^2)_2$, $-[C(R^3)_2]_n-NR^2SO_2A$, COR^2 , SO_2NR^2 and/or $S(O)_m A$,

Het¹ is a monocyclic or bicyclic, saturated, unsaturated or aromatic heterocyclic ring having 1 or 2 N, O and/or S atoms, which may be unsubstituted or monosubstituted or disubstituted by carbonyl oxygen, $=S$, $=N(R^3)_2$, Hal, A, OR^2 , $N(R^2)_2$, NO_2 , CN , $COOR^2$, $CON(R^2)_2$, NR^2COA , $NR^2CON(R^2)_2$, NR^2SO_2A , COR^2 , SO_2NR^2 and/or $S(O)_m A$,

Hal is F, Cl, Br or I,

n is 0, 1 or 2,

m is 0, 1 or 2,

o is 1, 2 or 3, or

a and pharmaceutically usable derivative, solvate, or stereoisomer derivatives, solvates and stereoisomers thereof, including mixtures thereof in all ratios.

2. (Currently Amended): A compound Compounds of the formula I according to Claim 1, in which

D is absent;

and pharmaceutically usable derivatives, solvates and stereoisomers thereof, including mixtures thereof in all ratios.

3. (Currently Amended): A compound ~~Compounds of the formula I according to~~ Claim 1, in which M is a phenyl ring;
~~and pharmaceutically usable derivatives, solvates and stereoisomers thereof,~~
~~including mixtures thereof in all ratios.~~

4. (Currently Amended): A compound ~~Compounds of the formula I according to~~ Claim 1, in which
D is a saturated, fully or partially unsaturated 3- to 4-membered alkylene chain, in which from 1 to 3 carbon atoms may be replaced by N and/or 1 or 2 carbon atoms may be replaced by 1 or 2 O and/or 1 or 2 S atoms, but where at most up to 3 carbon atoms are replaced and where, in addition, the alkylene chain and/or a nitrogen present therein may be monosubstituted, disubstituted or trisubstituted by Hal, A, OR² or N(R²)₂, and where, furthermore, one CH₂ group in the alkylene chain may also be replaced by a C=O group;
~~and pharmaceutically usable derivatives, solvates and stereoisomers thereof,~~
~~including mixtures thereof in all ratios.~~

5. (Currently Amended): A compound ~~Compounds of the formula I according to~~ Claim 1, in which
D is a saturated, fully or partially unsaturated 3- to 4-membered alkylene chain, in which from 1 to 3 carbon atoms may be replaced by N and/or 1 or 2 carbon atoms may be replaced by 1 or 2 O and/or 1 or 2 S atoms, but where at most up to 3 carbon atoms are replaced and where, in addition, the alkylene chain and/or a nitrogen present therein may be monosubstituted, disubstituted or trisubstituted by A or NH₂;
~~and pharmaceutically usable derivatives, solvates and stereoisomers thereof,~~
~~including mixtures thereof in all ratios.~~

6. (Currently Amended): A compound Compounds of the formula I according to Claim 1, in which

D is absent or is a saturated 3- to 4-membered alkylene chain, in which from 1 to 3 carbon atoms may be replaced by N and/or 1 or 2 carbon atoms may be replaced by 1 or 2 O atoms, but where at most up to 3 carbon atoms are replaced,

and where, in addition, the alkylene chain and/or a nitrogen atom located therein is unsubstituted, or may be monosubstituted or disubstituted by NH₂; and pharmaceutically usable derivatives, solvates and stereoisomers thereof, including mixtures thereof in all ratios.

7. (Currently Amended): A compound Compounds of the formula I according to Claim 1, in which

D is absent or is -CH=N-CH=CH-, -CH=CH-N=CH-, -NH-N=CH-, -CH=N-NH-, -O-N=CH- or -CH=N-O-,

and where, in addition, D is unsubstituted or may be monosubstituted by NH₂; and pharmaceutically usable derivatives, solvates and stereoisomers thereof, including mixtures thereof in all ratios.

8. (Currently Amended): A compound Compounds of the formula I according to Claim 1,

in which

R¹ is H, -[C(R³)₂]_n-N(R³)₂, CON(R²)₂, C(=S)NH₂ or N(R²)₂, and
R^{1'} is H,

and pharmaceutically usable derivatives, solvates and stereoisomers thereof, including mixtures thereof in all ratios.

9. (Currently Amended): A compound Compounds of the formula I according to Claim 1, in which

R¹ is H, CH₂NH₂, CONH₂, C(=S)NH₂ or NH₂, and
R^{1'} is H,

~~and pharmaceutically usable derivatives, solvates and stereoisomers thereof, including mixtures thereof in all ratios.~~

10. (Currently Amended): A compound Compounds of the formula I according to Claim 1, in which
W is a monocyclic saturated, unsaturated or aromatic carbocyclic or heterocyclic ring having 1 or 2 N, O and/or S atoms, which may be monosubstituted or disubstituted by R²;
~~and pharmaceutically usable derivatives, solvates and stereoisomers thereof, including mixtures thereof in all ratios.~~
11. (Currently Amended): A compound Compounds of the formula I according to Claim 1, in which
W is cyclohexanediyl, cyclopentanediyl, phenylene, biphenylene, furandiy, thiophenediy, pyrrolediy, imidazolediy, pyrazolediy, oxazolediy, isoxazolediy, thiazolediy, isothiazolediy, pyridinediy, pyrimidinediy, pyrrolidinediy, piperidinediy or piperazinediy, each of which is unsubstituted or monosubstituted or disubstituted by R²;
~~and pharmaceutically usable derivatives, solvates and stereoisomers thereof, including mixtures thereof in all ratios.~~
12. (Currently Amended): A compound Compounds of the formula I according to Claim 1, in which
W is pyrazolediy, which is unsubstituted or monosubstituted by A;
~~and pharmaceutically usable derivatives, solvates and stereoisomers thereof, including mixtures thereof in all ratios.~~
13. (Currently Amended): A compound Compounds of the formula I according to Claim 1, in which
X is CONH, CONHCH₂, CH₂NH or CH₂NHCH₂;
~~and pharmaceutically usable derivatives, solvates and stereoisomers thereof,~~

~~including mixtures thereof in all ratios.~~

14. (Currently Amended): A compound Compounds of the formula I according to Claim 1, in which
X is CONH₅,
~~and pharmaceutically usable derivatives, solvates and stereoisomers thereof,~~
~~including mixtures thereof in all ratios.~~
15. (Currently Amended): A compound Compounds of the formula I according to Claim 1, in which
Y is alkylene or Ar-diyl,
~~and pharmaceutically usable derivatives, solvates and stereoisomers thereof,~~
~~including mixtures thereof in all ratios.~~
16. (Currently Amended): A compound Compounds of the formula I according to Claim 1, in which
Y is phenylene which is unsubstituted or monosubstituted or disubstituted by A, Br, Cl or F,
~~and pharmaceutically usable derivatives, solvates and stereoisomers thereof,~~
~~including mixtures thereof in all ratios.~~
17. (Currently Amended): A compound Compounds of the formula I according to Claim 1, in which
T is a monocyclic saturated or unsaturated heterocyclic ring having from 1 to 3 N, O and/or S atoms, which is monosubstituted or disubstituted by =S, =NR², =NOR², =N-CN, =N-NO₂, =NCOR², =NCOOR² or =NOCOR², which is unsubstituted or and may be monosubstituted or disubstituted by A, CON(R²)₂ or COOR²,
~~and pharmaceutically usable derivatives, solvates and stereoisomers thereof,~~
~~including mixtures thereof in all ratios.~~

18. (Currently Amended): A compound Compounds of the formula I according to Claim 1, in which T is a monocyclic saturated or unsaturated heterocyclic ring having from 1 to 3 N, O and/or S atoms, which is monosubstituted or disubstituted by =S, =NR², =N-CN or =NOR², which is unsubstituted or and may be monosubstituted or disubstituted by A, CON(R²)₂ or COOR², and pharmaceutically usable derivatives, solvates and stereoisomers thereof, including mixtures thereof in all ratios.

19. (Currently Amended): A compound Compounds of the formula I according to Claim 1, in which T is piperidin-1-yl, pyrrolidin-1-yl, 1*H*-pyridin-1-yl, morpholin-4-yl, piperazin-1-yl, 1,3-oxazolidin-3-yl, 2*H*-pyridazin-2-yl, azepan-1-yl, 2-azabicyclo[2.2.2]octan-2-yl, pyrazol-2-yl, imidazolidin-1-yl, 1,3,4-thiadiazol-3-yl or 1,2-dihydropyrazol-2-yl, each of which is monosubstituted or disubstituted by =NR², =S, =N-CN or =NOR² and may furthermore be monosubstituted or disubstituted by A, CONH₂ or COOA₅, and pharmaceutically usable derivatives, solvates and stereoisomers thereof, including mixtures thereof in all ratios.

20. (Currently Amended): A compound Compounds of the formula I according to Claim 1, in which T is 2-iminopiperidin-1-yl, 2-iminopyrrolidin-1-yl, 2-imino-1*H*-pyridin-1-yl, 3-iminomorpholin-4-yl, 4-imino-1*H*-pyridin-1-yl, 2,6-diiminopiperidin-1-yl, 2-iminopiperazin-1-yl, 2,6-diiminopiperazin-1-yl, 2,5-diiminopyrrolidin-1-yl, 2-imino-1,3-oxazolidin-3-yl, 3-imino-2*H*-pyridazin-2-yl, 2-iminoazepan-1-yl, 2-hydroxy-6-iminopiperazin-1-yl, pyrazol-2-yl, 1,2-dihydropyrazol-2-yl, 2-methoxy-6-iminopiperazin-1-yl, 2-iminoimidazolidin-1-yl, 2-imino-1,3,4-thiadiazol-3-yl, 2-iminoimidazolidin-1-yl, and the corresponding hydroxyimino,

alkoxyimino, thioxo and $=N-(CH_2)_{1-3}NA'$ ₂ derivatives, where A' is alkyl having 1, 2, 3, 4, 5 or 6 carbon atoms, and where the heterocyclic rings are unsubstituted or may furthermore be monosubstituted or disubstituted by A, CONH₂ or COOA₂, ~~and pharmaceutically usable derivatives, solvates and stereoisomers thereof, including mixtures thereof in all ratios.~~

21. (Currently Amended): A compound Compounds of the formula I according to Claim 1, in which

T is 2-iminopyrrolidin-1-yl, 2-iminopiperidin-1-yl, 2-imino-1,3,4-thiadiazol-3-yl, 2-iminoimidazolidin-1-yl or 3-imino-1,2-dihdropyrazol-2-yl, and the corresponding hydroxyimino, alkoxyimino and thioxo derivatives, where the heterocyclic radicals are in each case unsubstituted or may furthermore be monosubstituted or disubstituted by A, CONH₂ or COOA₂, ~~and pharmaceutically usable derivatives, solvates and stereoisomers thereof, including mixtures thereof in all ratios.~~

22. (Currently Amended): A compound Compounds of the formula I according to Claim 1, in which

D is absent or is -CH=N-CH=CH-, -CH=CH-N=CH-, -NH-N=CH-, -CH=N-NH-, -O-N=CH- or -CH=N-O-,

M is a phenyl ring,

R¹ is H, CH₂NH₂, CONH₂, C(=S)NH₂ or NH₂,

R^{1'} is H,

W is a monocyclic saturated, unsaturated or aromatic carbocyclic or heterocyclic ring having 1 or 2 N, O and/or S atoms, which may be monosubstituted or disubstituted by R²,

R² is H or alkyl having 1, 2, 3, 4, 5 or 6 carbon atoms,

R^{2'} is H or alkyl having 1, 2, 3, 4, 5 or 6 carbon atoms,

X is CONH, CONHCH₂, CH₂NH or CH₂NHCH₂,

Y is alkylene or Ar-diyl,
Ar is phenyl, naphthyl or biphenyl, each of which is unsubstituted or monosubstituted, disubstituted or trisubstituted by Hal, A, OH, NH₂, NO₂, CN, COOH, CONH₂, NHCOA, NHCONH₂, NHSO₂A, COH, SO₂NH₂, S(O)_mA, -(CH₂)_n-COOR² or -O-(CH₂)_o-COOR²,
m and n are each, independently of one another, 0, 1 or 2,
o is 1, 2 or 3, and
T is piperidin-1-yl, pyrrolidin-1-yl, 1*H*-pyridin-1-yl, morpholin-4-yl, piperazin-1-yl, 1,3-oxazolidin-3-yl, 2*H*-pyridazin-2-yl, azepan-1-yl, 2-azabicyclo[2.2.2]octan-2-yl, pyrazol-2-yl, 1,3,4-thiadiazol-3-yl, imidazolidin-1-yl or 1,2-dihydropyrazol-2-yl, each of which is monosubstituted or disubstituted by =NR², =N-CN, =S or =NOR² and may furthermore be monosubstituted or disubstituted by A, CONH₂ or COOA₅,
~~and pharmaceutically usable derivatives, solvates and stereoisomers thereof, including mixtures thereof in all ratios.~~

23. (Currently Amended): A compound Compounds of the formula I according to Claim 1, in which

D is absent or is -CH=N-CH=CH-, -CH=CH-N=CH-, -NH-N=CH-, -CH=N-NH-, -O-N=CH- or -CH=N-O-,
M is a phenyl ring,
R¹ is H, CH₂NH₂, CONH₂, C(=S)NH₂ or NH₂,
R^{1'} is H,
W is cyclohexanediyl, cyclopentanediyl, phenylene, biphenylene, furandiyl, thiophenediyl, pyrrolediyl, imidazolediyl, pyrazolediyl, oxazolediyl, isoxazolediyl, thiazolediyl, isothiazolediyl, pyridinediyl, pyrimidinediyl or pyrrolidinediyl, each of which is unsubstituted or monosubstituted or disubstituted by R²,
R² is H or alkyl having 1, 2, 3, 4, 5 or 6 carbon atoms,

R^2 is H or alkyl having 1, 2, 3, 4, 5 or 6 carbon atoms,
 X is CONH, CONHCH₂, CH₂NH or CH₂NHCH₂,
 Y is phenylene which is unsubstituted or monosubstituted or disubstituted by A, Br, Cl or F,
 A is unbranched or branched alkyl having 1, 2, 3, 4, 5 or 6 carbon atoms and/or in addition 1-7 H atoms may be replaced by F, and
 T is piperidin-1-yl, pyrrolidin-1-yl, 1*H*-pyridin-1-yl, morpholin-4-yl, piperazin-1-yl, 1,3-oxazolidin-3-yl, 2*H*-pyridazin-2-yl, azepan-1-yl, 2-azabicyclo[2.2.2]octan-2-yl, pyrazol-2-yl, 1,3,4-thiadiazol-3-yl, imidazolidin-1-yl or 1,2-dihydropyrazol-2-yl, each of which is monosubstituted or disubstituted by =NR², =N-CN, =S or =NOR² and may furthermore be monosubstituted or disubstituted by A, CONH₂ or COOA₅,
~~and pharmaceutically usable derivatives, solvates and stereoisomers thereof, including mixtures thereof in all ratios.~~

24. (Currently Amended): A compound Compounds of the formula I according to Claim 1, in which

D is absent or is -CH=N-CH=CH-, -CH=CH-N=CH-, -NH-N=CH-, -CH=N-NH-, -O-N=CH- or -CH=N-O-,
 M is a phenyl ring,
 R^1 is H, CH₂NH₂, CONH₂, C(=S)NH₂ or NH₂,
 R^1' is H,
 W is pyrazolediyl or thiazolediyl, each of which is unsubstituted or monosubstituted by A,
 X is CONH,
 Y is phenylene which is unsubstituted or monosubstituted or disubstituted by A, Br, Cl or F, and
 T is 2-iminopyrrolidin-1-yl, 2-iminopiperidin-1-yl, 2-imino-1,3,4-thiadiazol-3-yl, 2-iminoimidazolidin-1-yl or 3-imino-1,2-dihydropyrazol-2-yl, and the corresponding hydroxyimino,

cyanoimino, alkoxyimino and thioxo derivatives, where the heterocyclic radicals are in each case unsubstituted or may furthermore be monosubstituted or disubstituted by A, CONH₂ or COOA,

A is unbranched or branched alkyl having 1, 2, 3, 4, 5 or 6 carbon atoms and/or in addition 1-7 H atoms may be replaced by F, ~~and pharmaceutically usable derivatives, solvates and stereoisomers thereof, including mixtures thereof in all ratios.~~

25. (Currently Amended): A compound ~~Compounds~~ according to Claim 1 selected from the group consisting of:

N-[4-(2-iminopyrrolidin-1-yl)phenyl]-2-(3-aminomethylphenyl)-5-trifluoromethyl-2H-pyrazole-3-carboxamide,
N-[4-(2-thioxopyrrolidin-1-yl)phenyl]-2-(3-aminocarbonylphenyl)-5-trifluoromethyl-2H-pyrazole-3-carboxamide,
N-[4-(2-methoxyiminopyrrolidin-1-yl)phenyl]-2-(3-aminocarbonylphenyl)-5-trifluoromethyl-2H-pyrazole-3-carboxamide,
N-[4-(2-iminopyrrolidin-1-yl)phenyl]-2-(3-aminobenzo[d]isoxazol-5-yl)-5-trifluoromethyl-2H-pyrazole-3-carboxamide,
N-[4-(2-imino-5-methyl-3H-1,3,4-thiadiazol-3-yl)phenyl]-2-(3-aminobenzo[d]isoxazol-5-yl)-5-trifluoromethyl-2H-pyrazole-3-carboxamide,
N-[4-(1,5-dimethyl-3-imino-1,2-dihydropyrazol-2-yl)phenyl]-2-(3-aminobenzo[d]isoxazol-5-yl)-5-trifluoromethyl-2H-pyrazole-3-carboxamide,
N-[4-(2-thioxopyrrolidin-1-yl)phenyl]-2-(3-aminobenzo[d]isoxazol-5-yl)-5-trifluoromethyl-2H-pyrazole-3-carboxamide,
N-[4-(2-methoxyiminopyrrolidin-1-yl)phenyl]-2-(3-amino-1H-indazol-5-yl)-5-trifluoromethyl-2H-pyrazole-3-carboxamide,
N-[4-(2-thioxopyrrolidin-1-yl)phenyl]-2-(3-amino-1H-indazol-5-yl)-5-trifluoromethyl-2H-pyrazole-3-carboxamide,
N-[4-(2-methoxyiminopyrrolidin-1-yl)phenyl]-2-(3-thiocarbamoylphenyl)-5-trifluoromethyl-2H-pyrazole-3-carboxamide,


N-[4-(2-hydroxyiminopyrrolidin-1-yl)phenyl]-2-(3-aminomethylphenyl)-5-trifluoromethyl-2*H*-pyrazole-3-carboxamide,
N-[3-methyl-4-(2-methoxyiminopyrrolidin-1-yl)phenyl]-2-(3-aminocarbonylphenyl)-5-trifluoromethyl-2*H*-pyrazole-3-carboxamide,
N-[4-(2-iminopyrrolidin-1-yl)phenyl]-2-(3-aminocarbonylphenyl)-5-trifluoromethyl-2*H*-pyrazole-3-carboxamide,
N-[3-bromo-4-(2-imino-5-methyl-3*H*-1,3,4-thiadiazol-3-yl)phenyl]-2-(3-aminocarbonylphenyl)-5-trifluoromethyl-2*H*-pyrazole-3-carboxamide,
N-[4-(2-imino-5-methyl-3*H*-1,3,4-thiadiazol-3-yl)phenyl]-2-(3-aminocarbonylphenyl)-5-trifluoromethyl-2*H*-pyrazole-3-carboxamide,
N-[4-(2-iminoimidazolidin-1-yl)phenyl]-2-(3-aminocarbonylphenyl)-5-trifluoromethyl-2*H*-pyrazole-3-carboxamide,
N-[4-(2-iminoimidazolidin-1-yl)-3-methylphenyl]-2-(3-amino-carbonylphenyl)-5-trifluoromethyl-2*H*-pyrazole-3-carboxamide,
N-[4-(2-cyanoiminoimidazolidin-1-yl)phenyl]-2-(3-amino-carbonylphenyl)-5-trifluoromethyl-2*H*-pyrazole-3-carboxamide,
N-[4-(2-cyanoimino-3-methylimidazolidin-1-yl)phenyl]-2-(3-aminocarbonylphenyl)-5-trifluoromethyl-2*H*-pyrazole-3-carboxamide,
N-[4-(2-imino-5-ethyl-3*H*-1,3,4-thiadiazol-3-yl)phenyl]-2-(3-aminocarbonylphenyl)-5-trifluoromethyl-2*H*-pyrazole-3-carboxamide,
N-[4-(2-imino-5-aminocarbonyl-3*H*-1,3,4-thiadiazol-3-yl)phenyl]-2-(3-aminocarbonylphenyl)-5-trifluoromethyl-2*H*-pyrazole-3-carboxamide,
N-[4-(2-imino-5-ethoxycarbonyl-3*H*-1,3,4-thiadiazol-3-yl)phenyl]-2-(3-aminocarbonylphenyl)-5-trifluoromethyl-2*H*-pyrazole-3-carboxamide,
N-[4-(2-imino-5-ethyl-3*H*-1,3,4-thiadiazol-3-yl)phenyl]-5-(3-aminocarbonylphenyl)-2-methylthiazole-4-carboxamide,
N-[4-(2-imino-5-ethyl-3*H*-1,3,4-thiadiazol-3-yl)phenyl]-2-(3-aminocarbonylphenyl)-5-methyl-2*H*-pyrazole-3-carboxamide,

and pharmaceutically usable derivatives, solvates and stereoisomers thereof, including mixtures thereof in all ratios.

26. (Currently Amended): A process ~~Process~~ for the preparation ~~a compound of~~ ~~compounds of the formula I~~ according to Claim 1, said process comprising: and ~~pharmaceutically usable derivatives, solvates and stereoisomers thereof,~~ ~~characterised in that~~

a) for the preparation of a compound ~~of the formula I~~
in which X is CONR^2 or $\text{CONR}^2\text{C}(\text{R}^3)_2$,

a compound of the formula II



in which

L is Cl, Br, I or a free or reactively functionally modified OH group,
~~and R¹, R², D, M and W are as defined in Claim 1,~~
with the proviso that any further OH and/or amino group present is protected,

is reacted with a compound of the formula III



in which

Z' is NHR^2 or $\text{NHR}^2\text{C}(\text{R}^3)_2$,
and R², Y and T are as defined in Claim 1,
and any protecting group is subsequently removed,

b) and/or in that a radical T, R¹ and/or R^{1'} ~~in a compound of the formula I~~
is converted into another radical T, R¹ and/or R^{1'}

by, for example,

- i) converting a sulfanyl compound into an imino compound,
- ii) removing an amino-protecting group,

and/or

a base or acid of the formula I is converted into one of its salts.

27. (Currently Amended): A method of inhibiting coagulation factor Xa in a patient, comprising administering to said patient a compound Compounds of the formula I according to Claim 1 as inhibitors of coagulation factor Xa.
28. (Currently Amended): A method of inhibiting coagulation factor VIIa in a patient, comprising administering to said patient a compound Compounds of the formula I according to Claim 1 as inhibitors of coagulation factor VIIa.
29. (Currently Amended): A pharmaceutical composition comprising a Medicament comprising at least one compound of the formula I according to Claim 1 and at least one excipient and/or adjuvant and/or pharmaceutically usable derivatives, solvates and stereoisomers thereof, including mixtures thereof in all ratios, and optionally excipients and/or adjuvants.
30. (Currently Amended): A pharmaceutical composition Medicament comprising at least one compound of the formula I according to Claim 29, further comprising 1 and/or pharmaceutically usable derivatives, solvates and stereoisomers thereof, including mixtures thereof in all ratios, and at least one further medicament active ingredient.
31. (Currently Amended): A method for treating Use of compounds according to Claim 1 and/or physiologically acceptable salts and solvates thereof for the preparation of a medicament for the treatment of thromboses, myocardial

infarction, arteriosclerosis, inflammation, apoplexia, angina pectoris, restenosis after angioplasty, claudicatio intermittens, migraine, tumours, tumour diseases and/or tumour metastases in a patient, comprising administering to said patient a compound according to claim 1.

32. (Currently Amended): A kit Set (kit) consisting of separate packs of
 - (a) an effective amount of a compound of the formula I according to Claim 1 and/or pharmaceutically usable derivatives, solvates and stereoisomers thereof, including mixtures thereof in all ratios, and
 - (b) an effective amount of a further medicament active ingredient.
33. (Currently Amended): A method according to claim 31, further comprising administering to said patient Use of compounds of the formula I according to Claim 1 and/or pharmaceutically usable derivatives, solvates and stereoisomers thereof, including mixtures thereof in all ratios, for the preparation of a medicament for the treatment of thromboses, myocardial infarction, arteriosclerosis, inflammation, apoplexia, angina pectoris, restenosis after angioplasty, claudicatio intermittens, migraine, tumours, tumour diseases and/or tumour metastases, in combination with at least one further medicament active ingredient.
34. (New): A compound according to claim 1, wherein
D is absent,
M is phenyl,
W is pyrazolediyl which is unsubstituted or monosubstituted or disubstituted by A, CONH₂ or COOA,
X is CONH,
Y is Ar-diyl,
Ar is phenyl which is unsubstituted or monosubstituted, disubstituted or trisubstituted by Hal, A, OH, NH₂, NO₂, CN, COOH, CONH₂, NHCOA,

NHCONH₂, NHSO₂A, COH, SO₂NH₂, S(O)_mA, -(CH₂)_n-COOR² or -O-(CH₂)_o-COOR², and

T is piperidin-1-yl, pyrrolidin-1-yl, 1*H*-pyridin-1-yl, morpholin-4-yl, piperazin-1-yl, 1,3-oxazolidin-3-yl, 2*H*-pyridazin-2-yl, azepan-1-yl, 2-azabicyclo[2.2.2]octan-2-yl, pyrazol-2-yl, 1,3,4-thiadiazol-3-yl, imidazolidin-1-yl or 1,2-dihydropyrazol-2-yl, each of which is monosubstituted or disubstituted by =NR², =N-CN, =S or =NOR² and may furthermore be monosubstituted or disubstituted by A, CONH₂ or COOA.

35. (New): A compound according to claim 34, wherein T is 2-iminopyrrolidin-1-yl, 2-iminopiperidin-1-yl, 2-imino-1,3,4-thiadiazol-3-yl, 2-iminoimidazolidin-1-yl, 3-imino-1,2-dihydropyrazol-2-yl, 2-hydroxyiminopyrrolidin-1-yl, 2-hydroxyiminopiperidin-1-yl, 2-hydroxyimino-1,3,4-thiadiazol-3-yl, 2-hydroxyiminoimidazolidin-1-yl, 3-hydroxyimino-1,2-dihydropyrazol-2-yl, 2-thioxopyrrolidin-1-yl, 2-thioxopiperidin-1-yl, 2-thioxo-1,3,4-thiadiazol-3-yl, 2-thioxoimidazolidin-1-yl, or 3-thioxo-1,2-dihydropyrazol-2-yl.
36. (New): A compound according to claim 34, wherein T is pyrrolidin-1-yl or 1,3,4-thiadiazol-3-yl which in each case is monosubstituted or disubstituted by =NR², =N-CN, =S or =NOR² and is further optionally monosubstituted or disubstituted by A, CONH₂ or COOA.
37. (New): A compound according to claim 36, wherein T is pyrrolidin-1-yl which is monosubstituted or disubstituted by =NR², =N-CN, =S or =NOR² and is further optionally monosubstituted or disubstituted by A, CONH₂ or COOA.
38. (New): A compound according to claim 36, wherein T is 1,3,4-thiadiazol-3-yl which is monosubstituted or disubstituted by =NR², =N-CN, =S or =NOR² and is further optionally monosubstituted or disubstituted by A, CONH₂ or COOA.
39. (New): A compound according to Claim 34, wherein

R^1 is H, $-[C(R^3)_2]_n-N(R^3)_2$, $CON(R^2)_2$, $C(=S)NH_2$ or $N(R^2)_2$, and
 $R^{1'}$ is H.

40. (New): A compound according to Claim 39, wherein R^1 is H, CH_2NH_2 , $CONH_2$, $C(=S)NH_2$ or NH_2 .
41. (New): A compound according to Claim 35, wherein
 R^1 is H, $-[C(R^3)_2]_n-N(R^3)_2$, $CON(R^2)_2$, $C(=S)NH_2$ or $N(R^2)_2$, and
 $R^{1'}$ is H.
42. (New): A compound according to Claim 41, wherein R^1 is H, CH_2NH_2 , $CONH_2$, $C(=S)NH_2$ or NH_2 .
43. (New): A compound according to Claim 37, wherein
 R^1 is H, $-[C(R^3)_2]_n-N(R^3)_2$, $CON(R^2)_2$, $C(=S)NH_2$ or $N(R^2)_2$, and
 $R^{1'}$ is H.
44. (New): A compound according to Claim 43, wherein R^1 is H, CH_2NH_2 , $CONH_2$, $C(=S)NH_2$ or NH_2 .